okay, fair enough.
The dilution of Musclepharm this year, just blew all projections and that just scares the hell out of many shareholders....in particular at a time where the seed capital is gone and Musclepharm is struggling to turn a profit.
Musclepharm is running out of tools in the tool box and that is highly concerning. Only comfort is the SEC investigation. Im afraid that without the SEC, Musclepharm wouldn't be a $10 stock.
There is just no need for any non existential dilution in the coming year.
If Musclepharm needs another pipe deal, then do it....but don't go buy back shares to issue stocks to God knows who.
Pipe deals are bad for stock performance, but it's nice to keep the option open.
In 2016, if Musclepharm turns a profit...well, then it can easily issue stock options and buy back shares. I just don't think now is the time. Also, the stock grants and stock options issued should not amount to more than 5% per year....in 2016, we should expect that Musclepharm is a regular company with a $250 million or so market cap.
Brad needs to get into his head that "less is sometimes more"....and if he feels that he might leave the company by then...Well, who says he cannot become a ceo of some other company? He got the connections to do whatever he wants to....his reputation is all that counts really.
News 
Market Data 
Discover 
